|
|
|
09100
|
|
|
P.I.:
|
Robert Morgan, MD
|
|
|
Title:
|
PHII-92, NCI#8233: A Phase II Trial of Temsirolimus and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer
|
| | |
|
|
09016
|
|
|
P.I.:
|
Robert Morgan, MD
|
|
|
Title:
|
GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Peritoneal Primary and Fallopian Tube Cancer
|
| | |
|
|
08240
|
|
|
P.I.:
|
Robert Morgan, MD
|
|
|
Title:
|
PHI-63 NCI #8282: A Phase I Study of Chronically-Dosed, Single Agent ABT-888 in patients with Either BRCA 1/2-Mutated Cancer: Platinum Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal Like Breast Cancer
|
| | |
|
|
06220
|
|
|
P.I.:
|
Robert Morgan, MD
|
|
|
Title:
|
PHII-80 PHL-051 NCI #7502: A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas
|
| | |
|
|
03109
|
|
|
P.I.:
|
Robert Morgan, MD
|
|
|
Title:
|
A Phase I Trial of PS-341 in Combination with Topotecan in Advanced Solid Tumor Malignancies
|
| | |
|